Long-term oral treatment with BAY 41-2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model

BJU International

Volumn 108, Issue 1, 2011, Pages 116-122

  Claudino, Mário A ^a   Da Silva, Fabio H ^a   Mõnica, Fabíola Z T ^a   Rojas Moscoso, Julio A ^a   De Nucci, Gilberto ^a   Antunes, Edson ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

BAY 41 2272; erectile dysfunction; erection; soluble guanylyl cyclase

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ACETYLCHOLINE; CYCLIC GMP; NITRIC OXIDE; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ERECTILE DYSFUNCTION; HYDROLYSIS; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE RELAXATION;

ANIMALS; CYCLIC GMP; ENZYME INHIBITORS; ERECTILE DYSFUNCTION; GUANYLATE CYCLASE; MALE; MUSCLE RELAXANTS, CENTRAL; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PENILE ERECTION; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR;

EID: 79958175354     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09776.x     Document Type: Article

References (36)

1. Andersson KE,. Pharmacology of penile erection. Pharmacol Rev 2001; 53: 417-50
2. Burnett AL,. Nitric oxide in the penis: physiology and pathology. Am J Urol 1997; 157: 320-424
3. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ,. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-4
4. Andersson KE, Wagner G,. Physiology of penile erection. Physiol Rev 1995; 75: 191-236
5. Sandner P, Neuser D, Bischoff E,. Erectile dysfunction and lower urinary tract. Handb Exp Pharmacol 2009; 191: 507-31
6. Stasch JP, Becker EM, Alonso-Alija C, et al,. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001; 410: 212-5 (Pubitemid 32216593)
7. Stasch JP, Hobbs AJN,. O-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009; 191: 277-308
8. Evgenov OV, Pacher P, Schmidt PM, Haskõ G, Schmidt HH, Stasch JPN,. O-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 755-68 (Pubitemid 44323702)
9. Stasch JP, Schmidt P, Alonso-Alija C, et al,. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002; 136: 773-83 (Pubitemid 34785720)
10. Priviero FB, Baracat JS, Teixeira CE, Claudino MA, De Nucci G, Antunes E,. Mechanisms underlying rabbit aorta relaxation by BAY 41-2272, a nitric oxide independent soluble guanylate cyclase activator. Clin Exp Pharmacol Physiol 2005; 32: 728-34 (Pubitemid 41603152)
11. Teixeira CE, Priviero FB, Webb RC,. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)- 1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl Indazole]. J Pharmacol Exp Ther 2006; 317: 258-66
12. Teixeira CE, Priviero FB, Todd J Jr, Webb RC,. Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms. Hypertension 2006; 596-602 (Pubitemid 43843882)
13. Kalsi JS, Rees RW, Hobbs AJ, et al,. BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol 2003; 169: 761-6 (Pubitemid 36133038)
14. Baracat JS, Teixeira CE, Okuyama CE, et al,. Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum. Eur J Pharmacol 2003; 477: 163-9 (Pubitemid 38373533)
15. Kalsi JS, Ralph DJ, Madge DJ, Kell PD, Cellek S,. A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats. Int J Impot Res 2004; 16: 479-85 (Pubitemid 39664854)
16. Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP,. BAY 41-2272: A stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology 2003; 61: 464-7 (Pubitemid 36206566)
17. Ribeiro MO, Antunes E, De Nucci G, Lovisolo SM, Zatz R,. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 1992; 20: 298-303
18. Moreno H Jr, Metze K, Bento AC, Antunes E, Zatz R, De Nucci G,. Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Bas Res Cardiol 1996; 91: 248-55 (Pubitemid 26229814)
19. Zanfolin M, Faro R, Araujo EG, Guaraldo AM, Antunes E, De Nucci G,. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol 2006; 47: 391-5 (Pubitemid 44309692)
20. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J,. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990; 170: 843-50 (Pubitemid 20249496)
21. Pickard RS, Powell PH, Zar MA,. The effect of inhibitors of nitric oxide biosynthesis and cyclic GMP formation on nerve-evoked relaxation of human cavernosal smooth muscle. Br J Pharmacol 1991; 104: 755-9
22. Trigo-Rocha F, Aronson WJ, Hohenfellner M, Ignarro LJ, Rajfer J, Lue TF,. Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs. Am J Physiol 1993; 264: H419-22 (Pubitemid 23081113)
23. Nakane M, Hsieh G, Miller LN, et al,. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int J Impot Res 2002; 14: 121-7 (Pubitemid 34450460)
24. Gur S, Kadowitz PJ, Hellstrom WJ,. Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction. Curr Pharm Des 2010; 16: 1619-33
25. Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med 2010; 7: 524-40
26. Kalsi JS, Ralph DJ, Thomas P, et al,. A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. J Sex Med 2005; 2: 53-7 (Pubitemid 40468192)
27. Claudino MA, Priviero FBM, Teixeira CE, De Nucci G, Antunes E, Zanesco A,. Protective effect of prior physical conditioning on relaxing response of corpus cavernosum from rats made hypertensive by nitric oxide inhibition. Int J Impotence Res 2007; 19: 189-95 (Pubitemid 46340838)
28. Gur S, Kadowitz PJ, Gurkan L, et al,. Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil. BJU Int 2010; 106: 78-83
29. phox Subunit of NAD(P)H oxidase contributes to erectile dysfunction caused by long-term nitric oxide inhibition in rats: reversion by regular physical training. Urology 2010; 75: 961-7
30. Imagawa A, Kimura K, Kawanishi Y, Tamura M,. Effect of moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue. Life Sci 1989; 44: 619-23 (Pubitemid 19064707)
31. Christ GJ, Maayani S, Valcic M, Melman A,. Pharmacological studies of human erectile tissue: characteristics of spontaneous contractions and alterations in alpha-adrenoceptor responsiveness with age and disease in isolated tissues. Br J Pharmacol 1990; 101: 375-81 (Pubitemid 20292893)
32. Blum MD, Bahnson RR, Porter TN, Carter MF,. Effect of local alpha-adrenergic blockade on human penile erection. J Urol 1985; 134: 479-81 (Pubitemid 16236377)
33. Brindley GS,. Maintenance treatment of erectile impotence by cavernosal unstriated muscle relaxant injection. Br J Psych 1986; 149: 210-5 (Pubitemid 16076253)
34. Carneiro FS, Giachini FR, Lima VV, et al,. DOCA-salt treatment enhances responses to endothelin-1 in murine corpus cavernosum. Can J Physiol Pharmacol 2008; 86: 320-8 (Pubitemid 351821124)
35. Linder AE, Dorrance AM, Mills TM, Webb RC, Leite R,. Erectile function in two-kidney, one-clip hypertensive rats is maintained by a potential increase in nitric oxide production. J Sex Med 2009; 3: 279-85
36. Sáenz de Tejada I, Angulo J, Cellek S, et al,. Physiology of erectile function. J Sex Med 2004; 1: 254-65 (Pubitemid 40424634)